Vaccines: a study raises the debate over adjuvants

A few months before the entry into force, in January, 2018, of the extension of the mandatory eight additional vaccinations, and more of the three that are today, the questio n of the potential risks of the basis of aluminum adjuvants returns

A report, revealed by the Parisian, Friday, September 22, of the national security agency of the drug (MSNA) on work of the team of the Professor Romain Gherardi (Inserm and University Hospital Henri-Mondor de Créteil, AP – HP) that she funded comes to reopen this debate, already very heated. In mice, they show a shift from aluminum to the brain. In a notice dated March 2017 and that was put online after the publication of the Parisian, the Scientific Council of the Agency concludes that “the contribution of the study to the knowledge on the safety of vaccines seems significant, not yet decisive”, and that they must be reproduced and in-depth.

The Advanced view the strengths and weaknesses of the work while emphasizing ‘the quality of the teams’ leading studies, which are “very recognized in their field.

A tone that was not always the welcoming research from Professor Gherardi, he leads for two decades.

In the wake of this opinion of the Scientific Council, a press conference with the team of Professor Gherardi was organised by the association E3M. The latter brings together individuals with myofasciitis macrophages, a complex disease that would, according to the association, induced by the basis of aluminum adjuvants. It translates among other joint pain, fatigue, cognitive impairment.. ..

So far, 600 cases were diagnosed by hospital Henri neuromuscular disease center – genetic Mondor. Terrain? The hype raises questions, particularly on the scope of work and funding. . To demonstrate the. ..

.. .

Leave a Reply

Your email address will not be published.